Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Orchard Therapeutics Plc ADR (NQ: ORTX ) N/A UNCHANGED Last Price Updated: 4:00 PM EST, Jan 23, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Orchard Therapeutics Plc ADR < Previous 1 2 3 4 5 Next > Why Orchard Therapeutics Shares Are Trading Higher By Around 95%; Here Are 20 Stocks Moving Premarket October 05, 2023 Gainers Via Benzinga Why Is Meiwu Technology (WNW) Stock Up 70% Today? October 05, 2023 Meiwu Technology is on the move Thursday with heavy trading of WNW stock despite lack of news or filings to explain the rally! Via InvestorPlace Why Is Orchard Therapeutics (ORTX) Stock Up 98% Today? October 05, 2023 Orchard Therapeutics stock is rising higher on Thursday as Kyowa Kirin agrees to acquire ORTX shares for $16 each in a $387.4 million deal. Via InvestorPlace Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday October 05, 2023 Pre-market stock movers are rising and falling on Thursday as we check out all of the latest news worth knowing about this morning! Via InvestorPlace Earnings Scheduled For August 3, 2023 August 03, 2023 Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million. Via Benzinga Why Gene Therapy Company Orchard Therapeutics Stock Is Skyrocketing Today? October 05, 2023 Gene therapy company Orchard Therapeutics Plc (NASDAQ: ORTX) shares are trading higher after it agreed to be acquired by Kyowa Kirin Co., a Japan-based global specialty pharmaceutical company, for... Via Benzinga Kyowa Kirin to Acquire Orchard Therapeutics October 05, 2023 From Orchard Therapeutics (Europe) Limited; Kyowa Kirin Co., Ltd. Via GlobeNewswire Are Gene Therapy Stocks The Market's Next Big Winners? September 25, 2023 Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price. Via MarketBeat Topics Artificial Intelligence Exposures Artificial Intelligence Orchard Therapeutics Announces Acceptance of Biologics License Application for OTL-200 in MLD and Receives Priority Review September 18, 2023 From Orchard Therapeutics (Europe) Limited Via GlobeNewswire Orchard Therapeutics Announces Presentation of Data Comprising the Clinical Package for the OTL-200 BLA in MLD at the SSIEM Annual Symposium 2023 August 31, 2023 From Orchard Therapeutics (Europe) Limited Via GlobeNewswire Orchard Therapeutics Completes Submission of Biologics License Application for OTL-200 in MLD to U.S. FDA August 03, 2023 From Orchard Therapeutics (Europe) Limited Via GlobeNewswire Orchard Therapeutics Strongly Supports Enactment of Newborn Metabolic Screening Act in Illinois, Adding Metachromatic Leukodystrophy to Statewide Panel August 02, 2023 From Orchard Therapeutics (Europe) Limited Via GlobeNewswire Orchard Therapeutics to Webcast Conference Call of Second Quarter 2023 Financial Results July 25, 2023 From Orchard Therapeutics (Europe) Limited Via GlobeNewswire Orchard Therapeutics Announces Second Closing of Strategic Financing, Resulting in $34 Million of Additional Capital June 26, 2023 From Orchard Therapeutics (Europe) Limited Via GlobeNewswire Orchard Therapeutics to Present at Stifel’s Genetic Medicines Day May 24, 2023 From Orchard Therapeutics (Europe) Limited Via GlobeNewswire Why Orchard Therapeutics Stock Is Trading Higher Today May 19, 2023 Orchard Therapeutics Inc (NASDAQ: ORTX) announced multiple clinical and preclinical updates from its portfolio of investigational hematopoietic stem cell (HSC) gene therapies in neurometabolic Via Benzinga Orchard Therapeutics Announces Positive Clinical and Preclinical Data in Programs Targeting Neurometabolic and CNS Disorders at ASGCT May 19, 2023 From Orchard Therapeutics (Europe) Limited Via GlobeNewswire Orchard Therapeutics Presents Data from Research Programs at ASGCT Demonstrating the Ability of HSC Gene Therapy to Address Larger Indications May 18, 2023 From Orchard Therapeutics (Europe) Limited Via GlobeNewswire Orchard Therapeutics Reports First Quarter 2023 Financial Results and Announces Initiation of Rolling Submission for Biologics License Application of OTL-200 for Metachromatic Leukodystrophy to U.S. FDA May 15, 2023 From Orchard Therapeutics (Europe) Limited Via GlobeNewswire Orchard Therapeutics Announces New Clinical and Pre-clinical Data at ASGCT 2023 May 03, 2023 From Orchard Therapeutics (Europe) Limited Via GlobeNewswire Orchard Therapeutics to Present at Guggenheim Genomic Medicines and Rare Disease Day March 30, 2023 From Orchard Therapeutics (Europe) Limited Via GlobeNewswire NVIDIA To Rally Around 14%? Here Are 10 Other Analyst Forecasts For Tuesday March 28, 2023 B of A Securities cut the price target for Fox Corporation (NASDAQ: FOXA) from $42 to $34. B of A Securities analyst Jessica Reif Ehrlich downgraded the stock from Buy to Neutral. Fox shares fell 1.8%... Via Benzinga Orchard Therapeutics Completes ADS Ratio Change March 10, 2023 From Orchard Therapeutics (Europe) Limited Via GlobeNewswire Why Aclaris Therapeutics Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session March 06, 2023 Gainers Unicycive Therapeutics, Inc. (NASDAQ: UNCY) shares surged 159% to $1.27 after the company announced a private placement of up to $130 million in gross proceeds to commercialize and launch... Via Benzinga Orchard Therapeutics Provides Business Update and Reports 2022 Financial Results March 06, 2023 From Orchard Therapeutics (Europe) Limited Via GlobeNewswire Orchard Therapeutics Announces Strategic Financing Totalling up to $188 Million March 06, 2023 From Orchard Therapeutics (Europe) Limited Via GlobeNewswire Orchard Therapeutics to Present at Multiple Investor Conferences in March 2023 March 03, 2023 From Orchard Therapeutics (Europe) Limited Via GlobeNewswire Orchard Therapeutics Announces Agreement Enabling Reimbursed Access to Libmeldy for All Eligible MLD Patients in Sweden February 27, 2023 From Orchard Therapeutics (Europe) Limited Via GlobeNewswire Orchard Therapeutics Announces Presentation of Updated Integrated Analysis of OTL-200 in MLD and Reports Progress with Newborn Screening Efforts at the 19th Annual WORLDSymposium™ February 24, 2023 From Orchard Therapeutics (Europe) Limited Via GlobeNewswire Orchard Therapeutics Announces Proposed ADS Ratio Change February 10, 2023 From Orchard Therapeutics (Europe) Limited Via GlobeNewswire < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.